{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ffc1fe6b303132625aa8d15/66913f3fec11f59b4912d121?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Key considerations when preparing patients with ALL for CAR T-cell therapy","description":"<h3>During the&nbsp;ALL Hub&nbsp;Steering Committee meeting,&nbsp;André Baruchel&nbsp;chaired a discussion on “What&nbsp;are the&nbsp;key considerations when preparing patients with ALL for CAR T-cell&nbsp;therapy&nbsp;?”,&nbsp;featuring&nbsp;Andrea Biondi,&nbsp;Anita&nbsp;Rijneveld, and&nbsp;José María Ribera.&nbsp;</h3><p><br></p><p>The discussion topics included:&nbsp;</p><ul><li>Key considerations when selecting patients: stable disease, degree of antigen expression, burden of bone marrow disease, and number of circulating tumor blasts&nbsp;</li><li>Bridging therapy and lymphodepletion considerations&nbsp;</li><li>The impact of prior exposure to blinatumomab&nbsp;and&nbsp;inotuzumab&nbsp;on CAR T-cell outcomes&nbsp;</li><li>Indications for the use of&nbsp;tisagenlecleucel&nbsp;in pediatric ALL&nbsp;&nbsp;</li><li>Indications for the use of&nbsp;brexucabtagene&nbsp;autoleucel&nbsp;in adult ALL</li></ul>","author_name":"Scientific Education Support"}